TherapeuticsMD (TXMD) Cash from Discontinued Operations (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Cash from Discontinued Operations came in at -$9000.0 in Q2 2026, up 84.21% on a YoY basis from -$4885.7 in Q2 2025, and down 12.5% quarter-over-quarter from -$8000.0 in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) Cash from Discontinued Operations (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported Cash from Discontinued Operations for 6 consecutive years, with -$9000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Discontinued Operations rose 84.21% year-over-year to -$9000.0; the trailing twelve-month figure through Jun 2026 stood at $23000.0 (up 112.17% YoY), and the FY2025 full-year result was -$30000.0, up 93.15% from the prior year.
- Cash from Discontinued Operations declined to -$9000.0 in Q2 2026 per TXMD's latest filing, from -$8000.0 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at $136.5 million in Q2 2022 and bottomed at -$131.0 million in Q4 2022.
- Historically, Cash from Discontinued Operations has averaged -$2.2 million across 5 years, with a median of -$35000.0 in 2025.
- The widest YoY moves for Cash from Discontinued Operations: up 148.93% in 2023, down 110.01% in 2023.
- Over 5 years, Cash from Discontinued Operations stood at -$131.0 million in 2022, then soared by 97.8% to -$2.9 million in 2023, then surged by 99.83% to -$5000.0 in 2024, then tumbled by 40.0% to -$7000.0 in 2025, then slipped by 28.57% to -$9000.0 in 2026.
- According to Business Quant data, Cash from Discontinued Operations over the past three periods registered -$9000.0, -$8000.0, and -$7000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | -9,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9,000.00 |
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Mar 31, 2025 | -13,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -559,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | -2.88 Mn |
| Sep 30, 2023 | 3.57 Mn |
| Jun 30, 2023 | -1.28 Mn |
| Mar 31, 2023 | -24.47 Mn |
| Dec 31, 2022 | -131.01 Mn |
| Sep 30, 2022 | -7.30 Mn |
| Jun 30, 2022 | 136.53 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Sep 30, 2010 | 730,772.00 |